Literature DB >> 18759711

Drug-induced serotonin syndrome: a review.

Christina Sun-Edelstein1, Stewart J Tepper, Robert E Shapiro.   

Abstract

Serotonin syndrome, or serotonin toxicity (ST), is a clinical condition that occurs as a result of an iatrogenic drug-induced increase in intrasynaptic serotonin levels primarily resulting in activation of serotonin(2A) receptors in the central nervous system. The severity of symptoms spans a spectrum of toxicity that correlates with the intrasynaptic serotonin concentration. Although numerous drugs have been implicated in ST, life-threatening cases generally occur only when monoamine oxidase inhibitors are combined with either selective or nonselective serotonin re-uptake inhibitors. The triad of clinical features consists of neuromuscular hyperactivity, autonomic hyperactivity and altered mental status, which may present abruptly and progress rapidly. The awareness of ST is crucial not only in avoiding the unintentional lethal combination of therapeutic drugs but also in recognizing the clinical picture when it occurs so that treatment can be promptly initiated. In this review, the pathophysiology, clinical features, implicated drugs, diagnosis and treatment of ST are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18759711     DOI: 10.1517/14740338.7.5.587

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  22 in total

1.  Evaluation of drug interactions in patients treated with antidepressants at a tertiary care cancer center.

Authors:  Lincy Subha Lal; Amy Zhuang; Frank Hung; Chun Feng; Rebecca Arbuckle; Michael J Fisch
Journal:  Support Care Cancer       Date:  2011-04-26       Impact factor: 3.603

Review 2.  Reducing safety-related drug attrition: the use of in vitro pharmacological profiling.

Authors:  Joanne Bowes; Andrew J Brown; Jacques Hamon; Wolfgang Jarolimek; Arun Sridhar; Gareth Waldron; Steven Whitebread
Journal:  Nat Rev Drug Discov       Date:  2012-12       Impact factor: 84.694

3.  PKCδ Knockout Mice Are Protected from Dextromethorphan-Induced Serotonergic Behaviors in Mice: Involvements of Downregulation of 5-HT1A Receptor and Upregulation of Nrf2-Dependent GSH Synthesis.

Authors:  Hai-Quyen Tran; Youngho Lee; Eun-Joo Shin; Choon-Gon Jang; Ji Hoon Jeong; Akihiro Mouri; Kuniaki Saito; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Mol Neurobiol       Date:  2018-02-22       Impact factor: 5.590

4.  Effects of opioids on human serotonin transporters.

Authors:  M Barann; U M Stamer; M Lyutenska; F Stüber; H Bönisch; B Urban
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-10-22       Impact factor: 3.000

5.  [Not Available].

Authors:  Annie Charbonneau
Journal:  Can J Hosp Pharm       Date:  2013-07

Review 6.  Serotonin syndrome: take a closer look at the unwell surgical patient.

Authors:  Z S Shaikh; S Krueper; T J Malins
Journal:  Ann R Coll Surg Engl       Date:  2011-11       Impact factor: 1.891

7.  Drug-induced movement disorder and confusion associated with duloxetine.

Authors:  Sarah Hasan Siddiqui; Nadeem Ahmed Memon; Ravi Shanker
Journal:  BMJ Case Rep       Date:  2018-03-28

8.  Linking pharmacology to clinical reports: cyclobenzaprine and its possible association with serotonin syndrome.

Authors:  J Mestres; S A Seifert; T I Oprea
Journal:  Clin Pharmacol Ther       Date:  2011-10-05       Impact factor: 6.875

Review 9.  Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.

Authors:  Hong-Wu Shen; Xi-Ling Jiang; Jerrold C Winter; Ai-Ming Yu
Journal:  Curr Drug Metab       Date:  2010-10       Impact factor: 3.731

Review 10.  Combination pharmacotherapy for psychiatric disorders in children and adolescents: prevalence, efficacy, risks and research needs.

Authors:  Jon Jureidini; Anne Tonkin; Elsa Jureidini
Journal:  Paediatr Drugs       Date:  2013-10       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.